Companion Animal Pharmaceuticals Market by Animal Type (Dogs, Cats, Horses), Route of Administration (Oral, Injectable, Topical), Indication (Antibiotics, Parasiticides), Distribution Channel (Veterinary Hospitals & Clinics) & Region - Global Forecasts to
Description
The global companion animal pharmaceuticals market is projected to reach USD 19.6 billion by 2027
from USD 14.4 billion in 2022, at a CAGR of 6.3% during the forecast period. The Rising prevalence of zoonotic diseases, Rising demand for pet insurance due to growing animal health expenditure, Increasing R&D investments for animal healthcare, Initiatives by various government agencies and animal associations, High pet ownership rates worldwide are some of the factors driving the growth of these markets. However, Rising pet care costs, Limited number of new product developments, High cost of vaccines and complexities associated with storage, Growing resistance to antimicrobials and antibiotics are restraining the growth of this market to a certain extent.
“The dermatologic diseases segment is projected to grow at the highest CAGR in the companion animal pharmaceuticals market.”
The dermatologic diseases segment is projected to grow at the highest CAGR during the forecast period. The rising need for advanced orthopedic drugs, increasing prevalence of arthritis, and growing pet population in developed and developing countries are some of the key factors driving the growth of this segment.
“In the forecast period, the dogs segment holds the largest share in the animal type segment.”
The dogs segment accounted for the largest market share in 2021. The large share of this segment is attributed to the increasing dog population and rising ownership rate in both developed and developing countries , rising canine healthcare expenditure, increasing prevalence of zoonotic diseases and other skin allergies in dogs, and the rising number of pet insurers across the globe.
“In the forecast period, by distribution channel segment, veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market”
During the forecast period, the veterinary hospitals segment is expected to grow at the highest CAGR. The higher adoption of animal parasiticides, analgesic, antimicrobials and antibiotics in hospital settings, rising cases of infectious diseases, increasing number of veterinary hospitals, growing ownership rate of companion animals, and rising veterinary expenditure are some of the key factors driving the growth of this segment.
“By Region, North America holds the largest share in the companion animal pharmaceuticals market, in the forecast period”
By Region, In 2021, North America accounted for the largest share of the companion animal pharmaceuticals market in the forecast period, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the high adoption rate of companion animals such as dogs and cats, well-established base of animal health industries, rising animal adoption centers, rising cases of parasitic infections, the large number of hospitals and clinics, growing expenditure on animal health in the region and , growing pool of veterinarians.
A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:
By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
By Designation: C-level–35%, Director Level–25%, and Others–40%
By Region: North America–40%, Asia- Pacific–30%, Europe–20%, Middle East & Africa–5%, Latin America- 5%
The prominent players in the global companion animal pharmaceuticals market are Zoetis, Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (US), Eco Animal Health Group PlC (UK), Virbac (France), Dechra Pharmaceuticals PLC (UK), Vetoquinol (France), Neogen Corporation (US), Orion Group (Finland), Zenex Animal Health India Private Limited (India), Norbrook Holdings Limited (UK), Chanelle Pharma (Ireland), HIPRA (Spain), Ceva Sante Animale (France), Tianjin Ringpu Bio-Technology Co Ltd. (China), Kyoritsu Seiyaku (Japan), Endovac Animal Health (US), Indian Immunologicals Ltd (India), Ashish Life Sciences Pvt Ltd (India), Lutim Pharma Pvt Ltd (India), Biogénesis Bagó (US), Brilliant Bio Pharma (India), Intas Pharmaceuticals (India), and Vetindia Pharmaceuticals limited (India).
Research Coverage:
This research report categorizes the companion animal pharmaceuticals market by indication, by route of administration, by animal type, by distribution channel and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion animal pharmaceuticals market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the companion animal pharmaceuticals market. Competitive analysis of upcoming startups in the C4ISR market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall C4ISR market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market
Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market
Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region
Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market
from USD 14.4 billion in 2022, at a CAGR of 6.3% during the forecast period. The Rising prevalence of zoonotic diseases, Rising demand for pet insurance due to growing animal health expenditure, Increasing R&D investments for animal healthcare, Initiatives by various government agencies and animal associations, High pet ownership rates worldwide are some of the factors driving the growth of these markets. However, Rising pet care costs, Limited number of new product developments, High cost of vaccines and complexities associated with storage, Growing resistance to antimicrobials and antibiotics are restraining the growth of this market to a certain extent.
“The dermatologic diseases segment is projected to grow at the highest CAGR in the companion animal pharmaceuticals market.”
The dermatologic diseases segment is projected to grow at the highest CAGR during the forecast period. The rising need for advanced orthopedic drugs, increasing prevalence of arthritis, and growing pet population in developed and developing countries are some of the key factors driving the growth of this segment.
“In the forecast period, the dogs segment holds the largest share in the animal type segment.”
The dogs segment accounted for the largest market share in 2021. The large share of this segment is attributed to the increasing dog population and rising ownership rate in both developed and developing countries , rising canine healthcare expenditure, increasing prevalence of zoonotic diseases and other skin allergies in dogs, and the rising number of pet insurers across the globe.
“In the forecast period, by distribution channel segment, veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market”
During the forecast period, the veterinary hospitals segment is expected to grow at the highest CAGR. The higher adoption of animal parasiticides, analgesic, antimicrobials and antibiotics in hospital settings, rising cases of infectious diseases, increasing number of veterinary hospitals, growing ownership rate of companion animals, and rising veterinary expenditure are some of the key factors driving the growth of this segment.
“By Region, North America holds the largest share in the companion animal pharmaceuticals market, in the forecast period”
By Region, In 2021, North America accounted for the largest share of the companion animal pharmaceuticals market in the forecast period, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the high adoption rate of companion animals such as dogs and cats, well-established base of animal health industries, rising animal adoption centers, rising cases of parasitic infections, the large number of hospitals and clinics, growing expenditure on animal health in the region and , growing pool of veterinarians.
A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:
By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
By Designation: C-level–35%, Director Level–25%, and Others–40%
By Region: North America–40%, Asia- Pacific–30%, Europe–20%, Middle East & Africa–5%, Latin America- 5%
The prominent players in the global companion animal pharmaceuticals market are Zoetis, Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (US), Eco Animal Health Group PlC (UK), Virbac (France), Dechra Pharmaceuticals PLC (UK), Vetoquinol (France), Neogen Corporation (US), Orion Group (Finland), Zenex Animal Health India Private Limited (India), Norbrook Holdings Limited (UK), Chanelle Pharma (Ireland), HIPRA (Spain), Ceva Sante Animale (France), Tianjin Ringpu Bio-Technology Co Ltd. (China), Kyoritsu Seiyaku (Japan), Endovac Animal Health (US), Indian Immunologicals Ltd (India), Ashish Life Sciences Pvt Ltd (India), Lutim Pharma Pvt Ltd (India), Biogénesis Bagó (US), Brilliant Bio Pharma (India), Intas Pharmaceuticals (India), and Vetindia Pharmaceuticals limited (India).
Research Coverage:
This research report categorizes the companion animal pharmaceuticals market by indication, by route of administration, by animal type, by distribution channel and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion animal pharmaceuticals market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the companion animal pharmaceuticals market. Competitive analysis of upcoming startups in the C4ISR market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall C4ISR market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market
Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market
Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region
Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market
Table of Contents
268 Pages
- STUDY OBJECTIVES
- MARKET DEFINITION
- CURRENCY CONSIDERED
- LIMITATIONS
- STAKEHOLDERS
- SUMMARY OF CHANGES
- RESEARCH APPROACH
- MARKET SIZE ESTIMATION
- DATA TRIANGULATION APPROACH
- MARKET SHARE ESTIMATION
- STUDY ASSUMPTIONS
- RISK ASSESSMENT
- LIMITATIONS
- IMPACT OF RECESSION
- EXECUTIVE SUMMARY
- COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW
- EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2021)
- COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2022-2027)
- COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. EMERGING MARKETS
- INTRODUCTION
- MARKET DYNAMICS
- INTRODUCTION
- INDUSTRY TRENDS
- PORTER'S FIVE FORCES ANALYSIS
- REGULATORY ANALYSIS
- VALUE CHAIN ANALYSIS
- SUPPLY CHAIN ANALYSIS
- ECOSYSTEM ANALYSIS
- PATENT ANALYSIS
- PRICING ANALYSIS
- KEY CONFERENCES AND EVENTS FROM 2023 TO 2024
- KEY STAKEHOLDERS & BUYING CRITERIA
- TRADE ANALYSIS
- INTRODUCTION
- INFECTIOUS DISEASES
- DERMATOLOGIC DISEASES
- PAIN
- ORTHOPEDIC DISEASES
- BEHAVIORAL DISORDERS
- OTHER INDICATIONS
- INTRODUCTION
- ORAL ADMINISTRATION
- INJECTABLE ADMINISTRATION
- TOPICAL ADMINISTRATION
- INTRODUCTION
- DOGS
- CATS
- HORSES
- OTHER COMPANION ANIMALS
- INTRODUCTION
- VETERINARY HOSPITALS
- VETERINARY CLINICS
- RETAIL PHARMACIES
- INTRODUCTION
- NORTH AMERICA
- EUROPE
- ASIA PACIFIC
- LATIN AMERICA
- MIDDLE EAST & AFRICA
- OVERVIEW
- REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS
- MARKET SHARE ANALYSIS
- COMPANY EVALUATION QUADRANT
- EVALUATION QUADRANT FOR STARTUPS/SMES
- COMPETITIVE BENCHMARKING
- COMPANY GEOGRAPHIC FOOTPRINT
- COMPETITIVE SITUATION AND TRENDS
- KEY PLAYERS
- OTHER PLAYERS
- INDUSTRY EXPERT INSIGHTS
- DISCUSSION GUIDE
- KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- CUSTOMIZATION OPTIONS
- RELATED REPORTS
- AUTHOR DETAILS
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
